Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status

ConclusionsAccording to HR status, HER2  + tumors express different pathways profiles: the overexpression of PI3K, MAPK and NOTCH pathways in HER2+/HR− group could justify different survival outcomes and treatment sensitivity. The identification of tumor driver pathways may be a useful instrument for individualized pathway-directed therapies. Further clinical implications are warranted.

Source: Journal of Cancer Research and Clinical Oncology - January 2, 2019 Category: Cancer & Oncology Source Type: research